Recent Updates
Recently added Catalysts
NRIX Positive Sentiment Score: 75/100

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Tuesday, January 2, 2024 2 min read
Key Takeaway: Nurix Therapeutics will present at the 42nd Annual J.P. Morgan Healthcare Conference, focusing on its achievements in 2023 and objectives for 2024. CEO Arthur T. Sands is scheduled to speak on January 8, 2024. The presentation will be available via live webcast and archived on the company's website. Nurix is known for its innovative approach to drug development, particularly in protein modulation for cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nurix Therapeutics is set to present its achievements and goals, highlighting progress in cancer treatment.
  • The company has developed innovative medicines targeting protein modulation, showcasing a unique approach.
  • The presentation at a prestigious conference indicates recognition and visibility in the biopharma space.
  • Nurix's integrated discovery platform, DELigase, emphasizes their cutting-edge research capabilities.

Full Press Release Details

SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT.
The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available on the Nurix website for 30 days after the event.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Frequently Asked Questions

What is Nurix Therapeutics focused on?

Nurix Therapeutics specializes in developing targeted protein modulation drugs for cancer treatment.

When will Nurix present at the J.P. Morgan Conference?

Nurix will present on January 8, 2024, at 3:00 p.m. PT.

How can I access the Nurix conference presentation?

The presentation will be available via webcast on Nurix's website under Events and Presentations.

What unique platform does Nurix use for drug discovery?

Nurix utilizes an integrated platform called DELigase to discover novel drug candidates.

Where is Nurix Therapeutics headquartered?

Nurix Therapeutics is headquartered in San Francisco, California.

Tags: NRIX Viatris Investor Conferences Healthcare Nurix Therapeutics cancer treatment biopharmaceutical J.P. Morgan Healthcare Conference
Last updated: Jan 2, 2024